Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
Utilizing Chemotherapy to Treat Lung Cancer
ASCO 2016 – Lung Cancer
Videos
Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer.
Related Items
IFCT-1001 CHIVA trial: A phase II study of carboplatin (Ca) plus pemetrexed (P) followed by P maintenance, as first-line therapy for human immunodeficiency virus (HIV)-associated advanced non-squamous non-small-cell lung cancer (NS-NSCLC)
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
An open-label phase 2 trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928)
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
E1505: Adjuvant chemotherapy ± bevacizumab for early stage NSCLC—outcomes based on chemotherapy subsets
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)
American Society of Clinical Oncology (ASCO)
ASCO 2016 – Lung Cancer
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us